Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2

Virology Journal

Volumn 8, Issue , 2011, Pages

  El Abd, Yasmine S ^a   Tabll, Ashraf A ^a   El Din, Noha ^a   Hosny, Alaa ^b   Moustafa, Rehab I ^a   El Shenawy, Reem ^a   Atef, Khaled ^a   El Awady, Mostafa K ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

anti E2 antibodies; candidate peptide vaccine for HCV; Hepatitis C virus (HCV); In vitro culture model for HCV; neutralizing antibodies

Indexed keywords

GLYCOPROTEIN E2; HEPATITIS C VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; NORLEUCINE; P412 VACCINE; P430 VACCINE; P517 VACCINE; UNCLASSIFIED DRUG; EPITOPE; GLYCOPROTEIN E2, HEPATITIS C VIRUS; HEPATITIS C ANTIBODY; HEPATITIS VACCINE; HVR1 PROTEIN, HEPATITIS C VIRUS; MONOCLONAL ANTIBODY; PEPTIDE; SUBUNIT VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

AGAR GEL ELECTROPHORESIS; ANIMAL EXPERIMENT; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FLOW CYTOMETRY; GENOTYPE; GOAT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFECTION PREVENTION; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; VIRUS CULTURE; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS REPLICATION; WESTERN BLOTTING; ANIMAL; ANTIBODY SPECIFICITY; ANTIGENIC VARIATION; CHEMISTRY; DRUG EFFECT; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; LIVER CELL CARCINOMA; NUCLEOTIDE SEQUENCE; PATHOLOGY; SERODIAGNOSIS; TUMOR CELL LINE; VACCINATION; VIROLOGY;

CAPRA; CAPRA HIRCUS; HEPATITIS C VIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; ANTIGENIC VARIATION; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CONSERVED SEQUENCE; EPITOPES; GOATS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; NEUTRALIZATION TESTS; PEPTIDES; VACCINATION; VACCINES, SUBUNIT; VIRAL ENVELOPE PROTEINS; VIRAL HEPATITIS VACCINES; VIRAL PROTEINS;

EID: 79961108533     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-391     Document Type: Article

References (43)

1. Epidemiology of Hepatitis C virus infection. Alte MJ, World J Gastroenterol 2007 13 17 2436 2441 17552026
2. Hepatitis C virus infection. Lauer GM, Walker BD, N Engl J Med 2001 345 41 52 10.1056/NEJM200107053450107 11439948 (Pubitemid 32634271)
3. Clinical outcomes after Hepatitis C infection from contaminated anti-d immune globulin. Irish hepatology research group. Kenny-Walsh E, N Engl J Med 1999 340 16 1228 1233 10.1056/NEJM199904223401602 10210705 (Pubitemid 29181642)
4. The natural history of Hepatitis C virus infection: Host, viral, and environmental factors. Thomas DL, Astemborski J, Rai RM, et al. JAMA 2000 284 4 450 456 10.1001/jama.284.4.450 10904508 (Pubitemid 30484478)
5. Estimating progression to cirrhosis in chronic Hepatitis C virus infection. Freeman AJ, Dore GJ, Law MG, et al. Hepatology 2001 34 4 (Part 1) 809 816 10.1053/jhep.2001.27831 11584380 (Pubitemid 32928008)
6. Outcome in a Hepatitis C (genotype 1b) single source outbreak in germany - a 25-year multicenter study. Wiese M, Grungreiff K, Guthoff W, et al. J Hepatol 2005 43 4 590 598 10.1016/j.jhep.2005.04.007 16237783 (Pubitemid 41253225)
7. Morbidity and mortality in paid austrian plasma donors infected with Hepatitis C at plasma donation in the 1970s. Ferenci P, Ferenci S, Datz C, et al. J Hepatol 2007 47 1 31 36 10.1016/j.jhep.2007.01.023 17335929 (Pubitemid 46817684)
8. Treating viral Hepatitis C: Efficacy, side effects, and complications. Manns MP, Wedemeyer H, Cornberg M, Gut 2006 55 9 1350 1359 10.1136/gut.2005. 076646 16905701 (Pubitemid 44277369)
9. Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread. Hangartner L, Zellweger RM, Giobbi M, et al. J Exp Med 2006 203 8 2033 2042 10.1084/jem.20051557 16880253 (Pubitemid 44188476)
10. Antiviral antibody responses: The two extremes of a wide spectrum. Hangartner L, Zinkernagel RM, Hengartner H, Nat Rev Immunol 2006 6 231 243 10.1038/nri1783 16498452 (Pubitemid 43290992)
11. Hepatitis C virus epitope-specific neutralizing antibodies in igs prepared from human plasma. Zhang P, Wu CG, Mihalik K, et al. Proc Natl Acad Sci USA 2007 104 20 8449 8454 10.1073/pnas.0703039104 17494735 (Pubitemid 47175508)
12. CD81 is dispensable for Hepatitis C virus cell-to-cell transmission in hepatoma cells. Witteveldt J, Evans MJ, Bitzegeio J, et al. J Gen Virol 2009 90 Part 1 48 58 10.1099/vir.0.006700-0 19088272
13. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. Bankwitz D, Steinmann E, Bitzegeio J, et al. J Virol 2010 84 11 5751 5763 10.1128/JVI.02200-09 20357091
14. Immunogenicity and safety of a novel therapeutic Hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Firbas C, Jilma B, Tauber E, et al. Vaccine 2006 24 20 4343 4353 10.1016/j.vaccine.2006.03.009 16581161
15. Therapeutic vaccination of chronic Hepatitis C nonresponder patients with the peptide vaccine ic41. Klade CS, Wedemeyer H, Berg T, et al. Gastroenterology 2008 134 5 1385 1395 10.1053/j.gastro.2008.02.058 18471515 (Pubitemid 351615373)
16. Conserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goats. El-Awady MK, Tabll AA, El-Abd YS, et al. Virol J 2009 6 66 10.1186/1743-422X-6-66 19473491
17. A simple, non-chromatographic procedure to purify immunoglobulins from serum and ascites fluid. McKinney MM, Parkinson A, J Immunol Methods 1987 96 2 271 278 10.1016/0022-1759(87)90324-3 3805742 (Pubitemid 17022661)
18. Purification of IgG from serum with caprylic acid and ammonium sulphate precipitation is not superior to ammonium sulphate precipitation alone. Mohanty JG, Elazhary Y, Comp Immunol Microbiol Infect Dis 1989 12 4 153 160 10.1016/0147-9571(89)90064-7 2612135 (Pubitemid 20081039)
19. HepG2 cells support viral replication and gene expression of Hepatitis C virus genotype 4 in vitro. El-Awady MK, Tabll AA, El-Abd YS, et al. World J Gastroenterol 2006 12 30 4836 4842 16937465 (Pubitemid 44323208)
20. Establishment of hybrid cell lines producing monoclonal antibodies to a synthetic peptide from the E1 region of the Hepatitis C virus. Tabll AA, Khalil SB, El-Shenawy RM, et al. J Immunoassay Immunochem 2008 29 1 91 104 18080883 (Pubitemid 350273990)
21. Establishment of persistent Hepatitis C virus infection and replication in vitro. Seipp S, Mueller HM, Pfaff E, et al. J Gen Virol 1997 78 Pt 10 2467 2476 9349466 (Pubitemid 27469988)
22. Hepatitis C virus infection of human hepatoma cell line 7721 in vitro. Song ZQ, Hao F, Minm F, et al. World J Gastroenterol 2001 7 5 685 689 11819854 (Pubitemid 32994420)
23. Using antibodies: A laboratory manual. Harlow E, Lane D, Cold Spring Harbor Laboratory Press 1999
24. Formation of native Hepatitis C virus glycoprotein complexes. Deleersnyder V, Pillez A, Wychowski C, et al. J Virol 1997 71 1 697 704 8985401 (Pubitemid 26412343)
25. Murine neutralizing antibody response and toxicity to synthetic peptides derived from E1 and E2 proteins of Hepatitis C virus. El-Awady MK, Tabll AA, Yousif H, et al. Vaccine 2010 28 52 8338 8344 10.1016/j.vaccine.2009.11.059 19995542
26. CD81 Is Required for Hepatitis C Virus Glycoprotein-Mediated Viral Infection. Zhang J, Randall G, Higginbottom A, et al. J Virol 2004 78 3 1448 1455 10.1128/JVI.78.3.1448-1455.2004 14722300 (Pubitemid 38095855)
27. How does Hepatitis C virus enter cells? Diedrich G, FEBS J 2006 273 17 3871 3885 10.1111/j.1742-4658.2006.05379.x 16934030 (Pubitemid 44253644)
28. Characterization of aggregates of Hepatitis C virus glycoproteins. Choukhi A, Pillez A, Drobecq H, et al. J Gen Virol 1999 80 12 3099 3107 10567640
29. Interaction of Hepatitis C virus-like particles and cells: A model system for studying viral binding and entry. Triyatni M, Saunier B, Maruvada P, et al. J Virol 2002 76 18 9335 9344 10.1128/JVI.76.18.9335-9344.2002 12186916 (Pubitemid 34919891)
30. Characterization of the genome and structural proteins of Hepatitis C virus resolved from infected human liver. Nielsen SU, Bassendine MF, Burt AD, et al. J Gen Virol 2004 85 6 1497 1507 10.1099/vir.0.79967-0 15166434 (Pubitemid 38807747)
31. Development and evaluation of a protein microarray chip for diagnosis of Hepatitis C virus. Yuk CS, Lee HK, Kim HT, et al. Biotechnol Lett 2004 26 20 1563 1568 15604797
32. Direct infection and replication of naturally occurring Hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures. Buck M, PLoS One 2008 3 7 2660 10.1371/journal.pone.0002660 18628977
33. Replication of Hepatitis C virus. Bartenschlager R, Lohmann V, J Gen Virol 2000 81 1631 1648 10859368 (Pubitemid 30427068)
34. Molecular economy and antibody function: The evolution of a protection. Langman RE, Int J Clin Lab Res 1992 22 2 63 68 10.1007/BF02591398 1504307
35. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Hsu M, Zhang J, Flint M, et al. Proc Natl Acad Sci USA 2003 100 12 7271 7276 10.1073/pnas.0832180100 12761383 (Pubitemid 36706428)
36. Evidence for crossgenotype neutralization of Hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein c1. Meunier JC, Engle RE, Faulk K, et al. Proc Natl Acad Sci USA 2005 102 12 4560 4565 10.1073/pnas.0501275102 15767578 (Pubitemid 40397151)
37. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Von Hahn T, Yoon JC, Alter H, et al. Gastroenterology 2007 132 2 667 678 10.1053/j.gastro.2006.12.008 17258731 (Pubitemid 46274668)
38. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Stamataki Z, Coates S, Evans MJ, et al. Vaccine 2007 25 45 7773 7784 10.1016/j.vaccine.2007.08.053 17919789 (Pubitemid 47588528)
39. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by Hepatitis C virus. Molina S, Castet V, Fournier-Wirth C, et al. J Hepatol 2007 46 3 411 419 10.1016/j.jhep.2006.09.024 17156886 (Pubitemid 46201721)
40. Cell culture models and animal models of viral hepatitis. Part II: Hepatitis C. Guha C, Lee SW, Chowdhury NR, et al. Lab Anim (NY) 2005 34 2 39 47 10.1038/laban0205-39 (Pubitemid 41673181)
41. Dynamic analysis of Hepatitis C virus replication and quasispecies selection in long-term cultures of adult human hepatocytes infected in vitro. Rumin S, Berthillon P, Tanaka E, et al. J Gen Virol 1999 80 11 3007 3018 10580063 (Pubitemid 29504674)
42. A candidate DNA vaccine elicits hcv specific humoral and cellular immune responses. Zhu LX, Liu J, Ye Y, et al. World J Gastroenterol 2004 10 17 2488 2492 15300890 (Pubitemid 39206765)
43. Therapeutic control of Hepatitis C virus: The role of neutralizing monoclonal antibodies. Keck ZY, Machida K, Lai MM, et al. Curr Top Microbiol Immunol 2008 317 1 38 10.1007/978-3-540-72146-8-1 17990788